. However, the lower sensitivity of CTC detection has been an issue, for example, less than half of men in SWOG 0925 had CTCs at baseline. 6 Identifying better prognostic and predictive biomarkers therefore remains a largely unmet need.
Circulating, blood-based microRNAs (miRNAs) are similar to circulating tumor cells (CTCs) in that they serve as promising, minimally invasive prostate cancer biomarker candidates. [7] [8] [9] [10] [11] MiRNAs are short (∼22 nucleotide) non-protein encoding RNAs that play an important role in regulation of gene expression via modulation of specific messenger RNA (mRNA) targets. 12 A single miRNA may regulate hundreds to thousands of mRNA transcripts and therefore may summarily reflect biological gene expression networks and provide complementary biological information to CTCs. MiRNAs may also be more sensitive and simple to assay than CTCs.
To explore the possibility that miRNAs may be more sensitive and easier to assay that CTCs and to see if miRNAs are predictive of PSA outcomes at 28 weeks, we prospectively collected correlative biospecimens on the randomized Phase II SWOG 0925 clinical trial. 8 We previously reported findings on CTCs and IGF-1R biomarkers, along with association to the primary endpoint of PSA after 28 weeks of therapy. To briefly summarize, of 50 patients that provided CTC samples, 39 had evaluable results and 16/39 (41%) had no detectable CTCs despite being collected from a population of patients with newly diagnosed metastatic prostate cancer.
Here, we report the results of our biomarker analysis of circulating miRNA in association with CTCs as well as with the primary endpoint of the clinical trial: PSA at 28 weeks, an outcome previously shown to correlate with overall survival. 13 We focused on five candidate circulating miRNAs which were previously identified via miRNA profiling and validated to be elevated in prostate cancer cases compared to controls: miR-141, miR200a, miR-200b, miR-210, and miR-375. 7 In addition, we used a wider profiling approach in which we examined plasma levels of 365 miRNAs to identify candidates whose baseline levels associated with the study endpoint of 28-week PSA as novel prognostic biomarker candidates.
| PATIENTS AND METHODS

| Patients
The randomized, Phase II SWOG S0925 study investigated androgen deprivation (AD) combined with cixutumumab versus AD alone in patients with new metastatic hormone-sensitive prostate cancer (ClinicalTrials.gov NCT01120236) has previously been described. 6 The results of the study did not show a significant difference in outcome between the two treatment arms, so we considered the patients in both arms in aggregate for the purpose of biomarker analyses. Eligible patients for the miRNA analysis were patients enrolled in SWOG 0925, had pathologic confirmation of prostate cancer, PSA ≥5 ng/mL, and at least one radiographic Briefly, upon arrival, plasma samples were centrifuged at 3,000g for 5 min at room temperature to separate the plasma, aliquoted into cryovials and stored at −80C. CTC measurements were performed using the clinical CellSearch® platform (Veridex) . Both timepoints from a single patient were extracted and run in the same batch to minimize batch effect.
| Quantification of circulating miRNAs
Total RNA was isolated from 200 µL plasma using the miRNeasy RNA isolation kit (Qiagen, Germany) in the following manner: Frozen aliquots were thawed on ice, centrifuged at 3,000g for 3 min at room temperature to remove additional cellular debris and insoluble components, 28 and 200 μL of plasma supernatant was measured and denatured using 10× volume (1 mL) Qiazol, vortexed and incubated at room temperature for 10 min. C. elegans spiked-in oligonucleotides were introduced (as a mixture of 25 fmol of each oligonucleotide in 5 μL total volume per liquid sample) after denaturation, which were used for normalization of variability in RNA isolation across samples as previously described. 7 RNA was extracted using 0.2× volume chloroform (220 μL), and total RNA was isolated following the manufacturer's protocol. For a given sample, RNA isolated from each 200 μL aliquot was eluted using 50 μL RNAsefree water at 1,000g, 3 min, 4°C. RNA was stored at −70°C.
Reverse transcription was performed in triplicate then pooled (to minimize batch effect) using 13 μL of RNA as input for the MirCURY Exiqon Universal RT kit following manufacturer's protocol.
Reaction was incubated at 42°C for 60 min followed by 5 min at 95C, 
| Study population and evaluable samples
Fifty patients participated in the translational science biomarker substudy (patient demographics shown in Table 1 ). Among these patients, one patient was ineligible for the trial, six patients initiated LHRH therapy prior to registration, and three patients lacked available samples for miRNA analysis. MiRNA data from the 40 remaining eligible and analyzable patients were used in these analyses. Baseline
CTCs were collected for all 40 patients mentioned above, but four CTC samples were not assessable, resulting in 36 eligible patients for the baseline CTC analysis.
| Statistical considerations
The Friedman test was used to assess correlations between the five previously validated, normalized miRNA data as ranks (due to lack of normally distributed data) and categories of baseline CTC counts, and We first examined whether baseline assessments of any of the five candidate circulating miRNAs are associated with baseline CTC counts ( Table 2 ). There was an association between baseline CTC counts and baseline circulating miR-141 (P = 0.0006), but not with baseline levels of the other four, miR-200a, miR-200c, miR-210 or miR-375.
| Correlation of five previously identified baseline miRNA and 28-week PSA response categories
We examined whether baseline assessments of any of the five candidate circulating miRNAs are associated with 28-week PSA response (Table 3) , the primary outcome of the clinical study, and thus serve as a prognostic biomarker at time of starting treatment. We observed a significant association between 28-week PSA response categories (PSA ≤ 0.2 ng/mL, 0.2 < PSA ≤ 4.0 ng/mL, PSA > 4.0 ng/mL) and circulating miR-375 (P = 0.001) and miR-200b (P = 0.005). In contrast, we did not observe a significant association between 28-week PSA response categories and miR-141 (P = 0.06), miR-200a (P = 0.32), or miR-210 (P = 0.59).
| Analysis to identify novel miRNA candidates
Following quantile normalization, we evaluated whether the miRNAs may be associated with baseline CTCs. The candidate miRNAs that are most strongly correlated with CTC categories are listed in Table 2 and those most correlated with 28-week PSA response categories are listed in Table 3 . All miRNAs are associated with baseline CTC and PSA response in Appendix Tables A and B) .
| DISCUSSION
In this companion, translational biomarker sub-study to the prospective randomized, Phase II SWOG 0925 study, we report our findings examining circulating miRNA biomarkers for treatment response prediction in a multi-center cooperative group clinical trial. This is an important step in demonstrating feasibility of miRNA assessment in the broader context of clinical practice.
Analysis from the SWOG 9346 clinical trial demonstrated that
PSA at 7-months (28-week) is prognostic for overall survival in men with newly diagnosed hormone sensitive metastatic prostate cancer 13 and therefore served as the primary endpoint for SWOG 0925. Here, we also evaluated the correlation of baseline circulating miRNA with the primary endpoint to determine if similar prognostic information could be gleaned at the start of initiation with AD and before the 7 months (28-week) timepoint. We found that baseline circulating miR-375 was associated with 28-week PSA, in both the candidate analysis and the discovery analysis. That we found the association through both analyses lends greater confidence in the results.
Multiple studies have identified miR-375 as elevated in advanced prostate cancer tumors, in circulating blood 11, 14, 15 and in urine. 16 Recent work suggests that miR-375 is involved in the epithelialmesenchymal-transition (EMT) signature, 17 and that disruption of this regulatory network may result in altered expression of miR-375.
Another recent report suggests miR-375 mediated repression of the tumor suppressor CBX7, a member of the Polycomb complex involved in epigenetic regulation, which may be associated with prostate tumorigenesis. 18 We sought to explore candidate miRNAs that we previously identified through differential examination of blood samples from metastatic prostate cancer patients and healthy controls, miR-141, miR-200a, miR-200c, miR-210, miR-375. It is possible that this approach could miss some candidate miRNAs and indeed following the discovery analysis, we identified a number of additional potential candidate miRNAs to be considered for further investigation (Tables 2 and 3 ). Given that the numbers of patients were relatively
small (approximately 34-40) and the number of miRNAs evaluated in parallel was substantially greater (365), we are cautious about overinterpreting the significance of these candidate miRNAs without further studies. Since the number of miRNAs evaluated was large, it is possible that a fraction were calculated to be significant by chance (ie, false positive). However, through simple mathematical calculation, we would expect about three from the discovery list to be significant and represent true positives. Further study will be needed for validation.
In reviewing the list of candidates identified through discovery analysis, some have been reported in the literature previously, either in association with biological processes such as in vitro studies, or in studies specifically to identify new prostate cancer biomarkers. It is interesting that the miR-200 family (especially miR-141) correlates with CTCs. The miR-200 family has been identified in other studies, and evidence suggests a role in the EMT. 7 A recent study suggests miR-141 may have multiple mechanisms for affecting tumor growth and metastase. 19 Another Phase 2 study of circulating miRNAs in patients with metastatic castration resistant prostate cancer treated with docetaxel identified miR-200 family members. 20 We and others have reported that miR-375 is elevated in plasma of CRPC patients. 11, [21] [22] [23] It is noteworthy that miR-375 is also made by non-prostate tissues including endocrine tissues, 24 and it is therefore possible that expression of miR-375 may reflect a tissue state affecting treatment response independent of CTCs. We are encouraged to find that miR-375 has also been reported in both plasma and urine from patient studies. 16, 25 Our findings add to the evidence that circulating miR-375 warrants further study in prospective clinical trials.
We previously reported on CTC enumeration using the CellSearch the sensitivity of CTC enumeration as well as specific molecular assessments of CTCs. 26, 27 In conclusion, we evaluated circulating miRNAs from the SWOG 0925 clinical trial in which 41% of patients had baseline CTC = 0. We found association between candidate miRNAs miR-141, miR-200a, miR-200c, and miR-375 levels were significantly correlated with the stratified baseline CTCs as enumerated by CellSearch, but the sample sizes were insufficient to determine whether circulating miRNAs may be more sensitive. Baseline miR-375 level and baseline CTC count were associated with the primary endpoint of 28-week PSA, providing the potential for prognostication at time of initiating AD. Finally, our discovery analysis identified novel potential candidate miRNAs, but more investigation is needed for confirmation.
Eventual survival outcomes from SWOG 0925 will be enlightening, and if our observation holds true in additional studies, baseline circulating miR-375 in combination with other clinical factors and biomarkers could serve to further stratify patients for future clinical trials and/or more intensified therapies. This works substantially adds to evidence for the role of circulating miRNAs as prostate cancer prognostic biomarkers.
